海正药业
(600267)
| 流通市值：110.83亿 | | | 总市值：110.89亿 |
| 流通股本：11.98亿 | | | 总股本：11.99亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,631,818,241.67 | 9,786,848,052.59 | 7,874,540,640.41 | 5,243,468,128.1 |
| 营业收入 | 2,631,818,241.67 | 9,786,848,052.59 | 7,874,540,640.41 | 5,243,468,128.1 |
| 二、营业总成本 | 2,362,401,236.88 | 9,027,322,865.05 | 7,323,584,992.31 | 4,907,475,802.86 |
| 营业成本 | 1,522,948,352.79 | 5,407,122,407.82 | 4,632,200,445.07 | 3,179,032,890.99 |
| 税金及附加 | 31,525,849.69 | 107,827,516.9 | 77,046,271.19 | 43,918,631.6 |
| 销售费用 | 504,930,925.85 | 2,128,788,534.69 | 1,583,085,460.85 | 999,873,586.74 |
| 管理费用 | 191,273,212.69 | 896,955,589.19 | 667,223,152.78 | 434,579,174.8 |
| 研发费用 | 92,429,291.9 | 357,688,684.68 | 262,633,894.43 | 177,546,214.57 |
| 财务费用 | 19,293,603.96 | 128,940,131.77 | 101,395,767.99 | 72,525,304.16 |
| 其中:利息费用 | 28,650,109.33 | 155,899,507.05 | 123,269,108.14 | 87,506,144.38 |
| 其中:利息收入 | 10,280,693.95 | 23,998,256.87 | 20,265,246.08 | 15,030,557.44 |
| 加:公允价值变动收益 | -2,565,091.57 | -14,926,284.66 | -13,227,309.09 | -116,840.31 |
| 加:投资收益 | -14,858,735.54 | 167,790,216.76 | 181,056,163.81 | 170,208,529.96 |
| 资产处置收益 | 113,471.7 | 722,661.2 | 1,737,175.59 | 2,682,933.65 |
| 资产减值损失(新) | -33,027,181.14 | -219,020,280.63 | -186,768,005.6 | -72,741,345.86 |
| 信用减值损失(新) | 1,984,974.24 | -86,750,100.09 | -15,108,301.56 | -20,320,046.66 |
| 其他收益 | 29,407,445.65 | 113,992,631.02 | 87,779,410.47 | 72,365,112.45 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 250,471,888.13 | 721,334,031.14 | 606,424,781.72 | 488,070,668.47 |
| 加:营业外收入 | 226,230.25 | 7,457,918.79 | 6,326,176.69 | 2,252,079.36 |
| 减:营业外支出 | 1,312,437.17 | 10,719,878.44 | 7,230,702.78 | 4,758,577.09 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 249,385,681.21 | 718,072,071.49 | 605,520,255.63 | 485,564,170.74 |
| 减:所得税费用 | 52,587,789.48 | 126,760,200.9 | 95,235,241.44 | 51,534,699.81 |
| 六、净利润 | 196,797,891.73 | 591,311,870.59 | 510,285,014.19 | 434,029,470.93 |
| 持续经营净利润 | 196,797,891.73 | 591,311,870.59 | 510,285,014.19 | 434,029,470.93 |
| 归属于母公司股东的净利润 | 194,227,169.89 | 601,182,827.25 | 515,312,975.68 | 435,241,383.97 |
| 少数股东损益 | 2,570,721.84 | -9,870,956.66 | -5,027,961.49 | -1,211,913.04 |
| (一)基本每股收益 | 0.17 | 0.52 | 0.44 | 0.37 |
| (二)稀释每股收益 | 0.17 | 0.52 | 0.44 | 0.37 |
| 八、其他综合收益 | -324,622.95 | 952,422.72 | -512,365.67 | -1,082,846.91 |
| 归属于母公司股东的其他综合收益 | -324,622.95 | 952,422.72 | -512,365.67 | -1,082,846.91 |
| 九、综合收益总额 | 196,473,268.78 | 592,264,293.31 | 509,772,648.52 | 432,946,624.02 |
| 归属于母公司股东的综合收益总额 | 193,902,546.94 | 602,135,249.97 | 514,800,610.01 | 434,158,537.06 |
| 归属于少数股东的综合收益总额 | 2,570,721.84 | -9,870,956.66 | -5,027,961.49 | -1,211,913.04 |
| 公告日期 | 2025-04-17 | 2025-03-29 | 2024-10-31 | 2024-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |